{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    10,
    20,
    23,
    24,
    30,
    31,
    32,
    34,
    35,
    36,
    39,
    41
  ],
  "modelUsed": "gemini-3-flash",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Background RA Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3.1",
        "sectionTitle": "Permitted Background RA Therapy",
        "description": "Reference for permitted background RA therapies for subjects failing to achieve LDA at Week 26"
      },
      {
        "id": "ref_2",
        "name": "TB Testing Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.1.1",
        "sectionTitle": "Study Procedures",
        "description": "Reference for specific requirements for TB testing and exclusionary parameters"
      },
      {
        "id": "ref_3",
        "name": "CYP3A Inhibitors Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Examples of Commonly Used Strong CYP3A Inhibitors and Inducers",
        "description": "Reference to the table listing prohibited CYP3A inhibitors and inducers"
      },
      {
        "id": "ref_4",
        "name": "Randomization Info Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.1.1",
        "sectionTitle": "Randomization/Drug Assignment",
        "description": "Reference for additional information on randomization and drug assignment"
      },
      {
        "id": "ref_5",
        "name": "Discontinuation Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.1",
        "sectionTitle": "Discontinuation of Study Drug and Continuation of Study Participation",
        "description": "Reference for details regarding premature discontinuation of study drug or participation"
      },
      {
        "id": "ref_6",
        "name": "Activity Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix E",
        "sectionTitle": "Study Activities (Period 2)",
        "description": "Reference to the schedule of activities for subjects who discontinue study drug but continue participation"
      },
      {
        "id": "ref_7",
        "name": "Contraception Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.4",
        "sectionTitle": "Contraception Recommendations",
        "description": "Reference for protocol-specified methods of birth control"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided within the clinical trial agreement.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Starting with Amendment 5, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Figure 2. Period 2 Study Design",
        "pageNumber": 35
      },
      {
        "id": "annot_3",
        "text": "Subjects with borderline serum pregnancy test at Screening must have a serum pregnancy test â‰¥ 3 days later to document continued lack of a positive result.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Inclusion Criteria",
        "pageNumber": 40
      },
      {
        "id": "annot_4",
        "text": "Questionnaires are not eligible for completion by virtual interview in the event that an onsite visit cannot be performed due to a pandemic.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Summary of Changes",
        "pageNumber": 5
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 7",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-12-04",
        "description": "Incorporating Administrative Changes 1-11 and Amendments 1-7; includes COVID-19 pandemic provisions",
        "amendmentNumber": "7"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment 6",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-06-30",
        "description": "Previous protocol version",
        "amendmentNumber": "6"
      },
      {
        "id": "ver_3",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-10-01",
        "description": "Original Protocol",
        "amendmentNumber": "N/A"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}